| NCT ID | NCT02141308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Retinal Artery Occlusions |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2014-05 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2014-05 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
Eligibility Criteria
Subject-Level Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to give informed consent. 2. Inability to complete study tests within a 30 day period 3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant. 4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). 5. Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. 6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography. Study-Eye Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to maintain stable fixation for OCT imaging. 2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract) 3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal). 4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.
Contact & Investigator
Thomas Hwang, MD
PRINCIPAL INVESTIGATOR
Oregon Health & Science Univeristy
Frequently Asked Questions
Who can join the NCT02141308 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 100 Years, studying Retinal Artery Occlusions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02141308 currently recruiting?
Yes, NCT02141308 is actively recruiting participants. Contact the research team at lathropk@ohsu.edu for enrollment information.
Where is the NCT02141308 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT02141308 clinical trial?
NCT02141308 is sponsored by Oregon Health and Science University. The principal investigator is Thomas Hwang, MD at Oregon Health & Science Univeristy. The trial plans to enroll 150 participants.